NIFTY? Becomes First CFDA Approved Non-Invasive Prenatal Genetic Test - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
NIFTY? Becomes First CFDA Approved Non-Invasive Prenatal Genetic Test


NIFTY™ Becomes First CFDA Approved Non-Invasive Prenatal Genetic Test

PR Newswire

COPENHAGEN, July 7, 2014 /PRNewswire/ --

BGI Diagnostics' NIFTY™ test becomes First NIPT based on Next Generation Sequencing Technology to be Approved by the China Food and Drug Administration (CFDA).

On June 30, 2014, the CFDA approved the registration of BGI's BGISEQ-1000 and BGISEQ-100 sequencers, and its prenatal genetic testing kits for NIFTY™ (Non-Invasive Fetal Trisomy test). This is the first genetic test based on next generation sequencing technology to be approved by the CFDA and makes the NIFTY™ test the only certified non-invasive prenatal test currently available in China.

The CFDA's approval for BGI's own-brand sequencers also highlights the fact that BGI has successfully transferred its technology from single to multiple platforms allowing the organisation to provide more varied product services in the field of genetic testing worldwide.

The NIFTY™ test is a highly accurate non-invasive maternal blood test, which detects the risk for certain fetal chromosomal (aneuploidy) disorders, such as Down syndrome, from as early as week 10 of pregnancy.

The NIFTY test is also provided across Europe, for more information please visit http://www.niftytest.com.

Contact: Xin Nyrop Han, +4570260806

 

SOURCE BGI

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here